-
-
-
-
-
-
-
William Blair Upgrades 10X Genomics (TXG) to Outperform
-
-
-
-
-
-
-
10X Genomics (TXG) PT Lowered to $20 at Leerink Partners
-
-
-
-
-
-
-
10x Genomics (TXG) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on 10X Genomics (TXG)
-
-
-
-
-
-
-
10x Genomics (TXG) 999 contracts of August 17.50 calls trade
-
-
-
-
-
-
-
10x Genomics (TXG) Tops Q3 EPS by 4c, Misses on Revenue; Offers FY24 Revenue Guidance
-
-
-
-
-
-
-
10x Genomics (TXG) sees revenue of approximately $151.7 million for the third quarter
-
422,576 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

